RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Eastern Hepatobiliary Surgery Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorEastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院)ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07285850, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery

    Exclusion criterion 6

  3. Positive for HIV antibody or Treponema pallidum antibody, or active hepatitis B/C infection

    Exclusion criterion 11

  4. Pregnant or breastfeeding women, or positive pregnancy test at baseline

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07285850, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Eligibility Criteria Inclusion Criteria

  • Age ≥ 18 years old (gender not limited)
  • ECOG performance status of 0-1
  • Preoperative imaging diagnosis of advanced hepatocellular carcinoma (BCLC stage C or D, unsuitable for surgery)
  • Ultrasound or MRI indicating moderate to severe fatty liver (Fibroscan CAP > 268 dB/m or MR fat score > 10%)
  • Willing to use contraceptive measures during the trial period
  • Expected survival time ≥ 3 months
  • At least one measurable lesion (per RECIST 1.1) that has not been irradiated
  • Organ function levels (within 7 days before first study medication) must meet the following:
  • Hematopoietic function: ANC ≥ 1.5×10⁹/L, PLT ≥ 100×10⁹/L, Hb ≥ 90 g/L, no transfusion within 14 days
  • Liver function: TBIL ≤ 1.5×ULN, AST/ALT/ALP ≤ 2.5×ULN, serum creatinine ≤ 1.5×ULN, CrCl ≥ 50 mL/min, ALB ≥ 30 g/L, Child-Pugh A
  • Coagulation function: INR and APTT ≤ 1.5×ULN or within therapeutic range if on anticoagulants
  • Renal function: urinary protein ≤ 1+ (or ≤1 g/24h if >1+)
  • Cardiac function: ECG normal or clinically insignificant, LVEF > 50%
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dosing
  • Men and women of reproductive potential must use effective contraception during and for 12 months after treatment
  • Participants must voluntarily provide informed consent and have good compliance

Exclusion Criteria

  • Excessive alcohol consumption (weekly ethanol intake: males < 210 g, females < 140 g)
  • Tumor lesions previously treated with targeted therapy, immunotherapy, TACE, or radiotherapy
  • Pregnant or breastfeeding women, or positive pregnancy test at baseline
  • Central nervous system metastases diagnosed by CT, MRI, or PET-CT
  • Participation in another clinical drug or therapy trial within 4 weeks before first study dose
  • Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery
  • Radiotherapy within 2 weeks before first study dose
  • History or presence of primary immunodeficiency or active autoimmune disease
  • History of organ transplantation or hematopoietic stem cell transplantation
  • Current use of immunosuppressants or corticosteroids (>10 mg/day prednisone or equivalent) within 2 weeks
  • Positive for HIV antibody or Treponema pallidum antibody, or active hepatitis B/C infection
  • Allergy to recombinant humanized PD-1 monoclonal antibody, VEGF monoclonal antibody, or components
  • Symptomatic pleural effusion, pericardial effusion, or ascites requiring clinical intervention
  • Severe cardiovascular disease within 12 months (e.g., CAD, CHF ≥ II, arrhythmias, MI)
  • Events within 6 months before first dose (e.g., DVT, PE, MI, PCI, ACS, CABG, stroke, TIA, embolism)
  • History of GI surgery, obstruction, bleeding, dysfunction, or malabsorption affecting drug absorption
  • Severe uncontrolled infection or comorbidity, or moderate/severe renal impairment
  • Active pulmonary disease (interstitial pneumonia, COPD, asthma, tuberculosis history)
  • Abnormal coagulation (INR > 2.0, PT > 16 s), bleeding tendency, or thrombolytic/anticoagulant therapy (except prophylaxis)
  • Significant bleeding within 3 months (e.g., hemoptysis ≥ 2.5 mL, GI bleeding, varices, ulcers, vasculitis)
  • Known hereditary/acquired bleeding or thrombotic disorders (e.g., hemophilia, thrombocytopenia)
  • History of substance abuse or mental disorders affecting compliance
  • Use of warfarin or coumarin derivatives within 14 days before or during treatment
  • Other severe acute/chronic conditions increasing risk or confounding results
  • Poor compliance or other conditions deemed unsuitable for trial participation

Quoted from ClinicalTrials.gov, NCT07285850, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07285850, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07285850